IRMD vs. OFIX, NVRO, EMBC, SIBN, OSUR, SKIN, TMCI, SRDX, ANIK, and PLSE
Should you be buying Iradimed stock or one of its competitors? The main competitors of Iradimed include Orthofix Medical (OFIX), Nevro (NVRO), Embecta (EMBC), SI-BONE (SIBN), OraSure Technologies (OSUR), Beauty Health (SKIN), Treace Medical Concepts (TMCI), Surmodics (SRDX), Anika Therapeutics (ANIK), and Pulse Biosciences (PLSE). These companies are all part of the "surgical & medical instruments" industry.
Orthofix Medical (NASDAQ:OFIX) and Iradimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings.
In the previous week, Iradimed had 9 more articles in the media than Orthofix Medical. MarketBeat recorded 15 mentions for Iradimed and 6 mentions for Orthofix Medical. Orthofix Medical's average media sentiment score of 0.45 beat Iradimed's score of 0.12 indicating that Iradimed is being referred to more favorably in the news media.
Orthofix Medical received 158 more outperform votes than Iradimed when rated by MarketBeat users. However, 64.69% of users gave Iradimed an outperform vote while only 61.78% of users gave Orthofix Medical an outperform vote.
Iradimed has lower revenue, but higher earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Iradimed has a net margin of 26.22% compared to Iradimed's net margin of -20.28%. Orthofix Medical's return on equity of 24.62% beat Iradimed's return on equity.
Orthofix Medical has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
89.8% of Orthofix Medical shares are held by institutional investors. Comparatively, 92.3% of Iradimed shares are held by institutional investors. 4.7% of Orthofix Medical shares are held by company insiders. Comparatively, 42.6% of Iradimed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Orthofix Medical currently has a consensus price target of $15.50, suggesting a potential upside of 19.32%. Iradimed has a consensus price target of $62.50, suggesting a potential upside of 49.31%. Given Orthofix Medical's stronger consensus rating and higher probable upside, analysts plainly believe Iradimed is more favorable than Orthofix Medical.
Summary
Iradimed beats Orthofix Medical on 15 of the 18 factors compared between the two stocks.
Get Iradimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iradimed Competitors List
Related Companies and Tools
